KC

Kalyani Chandrakant Raghuwanshi

Active Director Director DIN 10487335
DIN 10487335 First appointment Feb 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Kalyani Chandrakant Raghuwanshi

Data last updated:

Kalyani Chandrakant Raghuwanshi is a Director at Jrn Pharma Limited (since 2024).

DIN 10487335
Primary Designation Director
First Appointment 01 Feb 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jrn Pharma Limited U46497MH2024PLC418321
Director01 Feb 20242024Active

Board colleagues of Kalyani Chandrakant Raghuwanshi

NameDINCompanyDesignation
Chandrakant Batesing Raghuvanshi00205532Jrn Pharma LimitedWhole-Time Director
Jit Narayan Srivastava06924672Jrn Pharma LimitedWhole-Time Director

Directorship timeline

Open interactive timeline →
Jrn Pharma Limited
Premium access

Shareholding and investment profile for Kalyani Chandrakant Raghuwanshi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kalyani Chandrakant Raghuwanshi

Kalyani Chandrakant Raghuwanshi currently holds 1 directorship: Jrn Pharma Limited (Director, since 01 Feb 2024).

Kalyani Chandrakant Raghuwanshi was first appointed on 01 Feb 2024 as Director at Jrn Pharma Limited.

The current boards of Kalyani Chandrakant Raghuwanshi's companies include Chandrakant Batesing Raghuvanshi (Jrn Pharma Limited), Jit Narayan Srivastava (Jrn Pharma Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available